Invasive treatment and the associated stress are known risk factors for sodium-glucose cotransporter 2 inhibitor (SGLT2i)-induced euglycemic diabetic ketoacidosis (euDKA) development. Here, SLC5A2 is linked to diabetic ketoacidosis.